Assessment of microRNAs Role in Familial Mediterranean Fever FMF Pathophysiology (miRinFMF)
Familial Mediterranean Fever
About this trial
This is an interventional other trial for Familial Mediterranean Fever focused on measuring MEditerranean FeVer MEFV gene, micro ribonucleic acid miRNA
Eligibility Criteria
Inclusion Criteria: Patient aged ≥1 year Body weight ≥ 10kg Homozygous patients group: patients homozygous for MEFV (M694V, M694I, M680I, V726A) Symptomatic heterozygous patients group: patients heterozygous for the MEFV gene (M694V, M694I, M680I, V726A) meeting the Yalcinkaya criteria for FMF diagnosis (Fever lasting 6 to 72 hours with at least 3 attacks - Abdominal pain of 6 to 72 hours duration with at least 3 attacks - Chest pain of 6 to 72 hours duration with at least 3 attacks - Arthritis of 6 to 72 hours duration with at least 3 attacks- FMF Family History of FMF) Asymptomatic heterozygous patients group: patients heterozygous for the MEFV gene (M694V, M694I, M680I, V726A) who do not meet the Yalcinkaya criteria for FMF diagnosis Control subjects group: absence of identified auto-inflammatory disorder Exclusion Criteria: Absence of collection of informed consent of participant or absence of informed consent of the legal representatives/guardians of pediatric participant Subjects not registered in Social Security system
Sites / Locations
- University Hospital of Nîmes
- Robert Debré University Hospital of Paris
- University Hospital of Paris Kremlin Bicêtre
- University Hospital of Toulouse
Arms of the Study
Arm 1
Other
Blood Sampling
Collection of 10 ml of blood on EDTA tube during: Standard check-up visit as a part of the standard monitoring of the disorder for homozygous and symptomatic heterozygous patients Specific study visit for asymptomatic heterozygous patients Presurgery blood test for control subjects